Even after the COVID-19 pandemic, infectious diseases remain among the greatest challenges to global health. At the same time, advances in biomedical research, data-driven methods, and clinical innovation are opening up new opportunities to tailor prevention, diagnosis, and treatment to individual patients. How these approaches can be translated into medical care was the focus of the 2nd International Conference on Individualized Infection Medicine, which took place from March 19 to 21, 2026, at Herrenhausen Palace in Hannover.

Dr. Lina Herhaus has been awarded the Otto Meyerhof Award of the German Society for Biochemistry and Molecular Biology (GBM e.V.) at the 77th Mosbacher Kolloquium of the GBM. The prize, endowed with €5,000 and funded by Boehringer Ingelheim, was presented for the seventh time and recognizes outstanding early-career scientists conducting research in Germany in fields relevant to the GBM within biochemistry and molecular biology. The award commemorates the world-renowned physiologist and biochemist Otto Meyerhof, who worked in Kiel, Berlin, and Heidelberg before being forced to flee Germany in 1938 as a Jewish scientist.

Just in time for today’s World Tuberculosis Day, the new S3 guideline on tuberculosis prevention among newly arrived migrants has gone online at the Association of Scientific Medical Societies (AWMF). Commissioned by the German Respiratory Society (DGP), it was developed under the leadership of the German Central Committee for Tuberculosis Control (DZK) and the Helmholtz Centre for Infection Research (HZI). Over the past three years, a team of experts from the fields of public health and individual medicine worked together with affected individuals to improve tuberculosis screening—and thus prevention—in Germany. The guideline was funded by the Innovation Fund of the Joint Federal Committee (G-BA).